vatalanib has been researched along with Disease Exacerbation in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alsop, DC; de Bazelaire, C; George, D; Michaelson, MD; Pedrosa, I; Rofsky, NM; Wang, Y | 1 |
| Antoniadis, H; Christofori, G; Crnic, I; Littlewood-Evans, A; Schomber, T; Strittmatter, K; Wood, J; Zumsteg, A | 1 |
| Folprecht, G; Gatter, KC; Giatromanolaki, A; Harris, AL; Jalava, T; Koukourakis, MI; Laurent, D; Lebwohl, D; Meinhardt, G; Shi, MM; Sivridis, E; Trarbach, T | 1 |
| Higginson, A; Horsfield, MA; Kay, A; Laurent, D; Lee, L; Masson, E; Morgan, B; Puccio-Pick, M; Steward, WP; Thomas, AL | 1 |
| Bono, P; Bosselli, S; Casali, PG; Coco, P; De Braud, F; De Pas, T; Jalava, T; Joensuu, H; Laurent, D; Putzu, C; Spreafico, C | 1 |
| Bui, B; Italiano, A | 1 |
| Aaltola, EM; Alitalo, K; Häyry, PJ; Koskinen, PK; Krebs, R; Lemström, KB; Nykänen, AI; Sihvola, RK; Tikkanen, JM; Wood, J; Ylä-Herttuala, S | 1 |
1 review(s) available for vatalanib and Disease Exacerbation
| Article | Year |
|---|---|
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles | 2008 |
4 trial(s) available for vatalanib and Disease Exacerbation
| Article | Year |
|---|---|
Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Feasibility Studies; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Neoplasm Metastasis; Neovascularization, Pathologic; Phthalazines; Pyridines; Regional Blood Flow | 2008 |
Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Endothelial Cells; Female; Humans; Immunohistochemistry; Male; Middle Aged; Neovascularization, Pathologic; Phthalazines; Platelet Endothelial Cell Adhesion Molecule-1; Predictive Value of Tests; Prognosis; Pyridines; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Chi-Square Distribution; Chromatography, High Pressure Liquid; Disease Progression; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Phthalazines; Protein Kinase Inhibitors; Pyridines; Statistics, Nonparametric; Treatment Outcome | 2005 |
Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Proteins; Phthalazines; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy | 2008 |
2 other study(ies) available for vatalanib and Disease Exacerbation
| Article | Year |
|---|---|
Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Disease Progression; Lymphangiogenesis; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor | 2009 |
Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis.
Topics: Acute Disease; Angiogenesis Inhibitors; Animals; Arteriosclerosis; Chronic Disease; Disease Models, Animal; Disease Progression; Endothelial Growth Factors; Gene Transfer, Horizontal; Graft Rejection; Graft Survival; Heart Transplantation; Immunohistochemistry; In Situ Hybridization; Leukocytes, Mononuclear; Lymphokines; Macrophages; Myocardium; Phthalazines; Pyridines; Rabbits; Rats; Rats, Inbred Strains; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; RNA, Messenger; Transfection; Transplantation, Heterotopic; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |